𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fengabine in depression: A placebo-controlled study of a GABA agonist

✍ Scribed by E. S. Paykel; A. E. van Woerkom; D. E. Walters; W. White; J. Mercer

Book ID
102860276
Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
675 KB
Volume
6
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

A double-blind controlled trial of Fengabine, a GABA agonist, against placebo was carried out in outpatient major depressives. Subjects were treated for up to 6 weeks with Fengabine three times daily, using 900 mg daily in the first week and 1800 mg daily thereafter. A total of 49 subjects were included, of whom 32 completed 6 weeks. Efficacy analyses showed no evidence of superiority of active drug over placebo, and the two groups were closely comparable throughout the study. Fengabine was free of subjective side-effects other than a small number of complaints of nausea and diarrhoea, and some ocurrence of bright yellow urine. There was a substantial incidence of raised liver enzymes: 44 per cent of patients on Fengabine developed some de novo elevation, necessitating early termination of the study. The findings did not support any therapeutic value for this group of GABA agonists in depression.

📜 SIMILAR VOLUMES

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode